Novavax Inc. ($NVAX) Stock Forecast: Up 5.1% Today

What is Novavax Inc.?

Novavax Inc (NVAX) operates in the biotech industry and is known for its protein-based vaccine technology. Today, the stock exhibited a strong upward movement amidst a slightly negative trend in the broader market.

Why is Novavax Inc. going up?

NVAX stock is up 5.1% on Feb 13, 2026 19:26

• Novavax (NVAX) stock showed resilience today, increasing by 2.51% while major indices such as the S&P 500, Dow, and Nasdaq faced minor declines.
• Analysts hold a positive outlook on Novavax's upcoming financial performance, anticipating substantial growth in earnings and revenue, which is likely fueling the favorable market sentiment towards the stock.
• Investor interest in Novavax as a potential biotech success story, alongside its protein-based vaccine technology as an alternative to mRNA, has attracted capital despite the stock's inherent volatility and competition in the sector.
• Anticipated expansion in the Human Vaccine Adjuvants Market is also instilling confidence in Novavax's future potential, supported by ongoing advancements in vaccine technology and the global emphasis on personalized medicine driving industry growth.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Novavax (NVAX) Rises As Market Takes a Dip: Key Facts

Novavax (NVAX) stock rose by 2.51% (closing at $8.97) while the broader market dipped, outperforming the S&P 500, Dow, and Nasdaq. The vaccine maker's shares have gained 0.92% over the past month, contrasting with losses in the Medical sector and S&P 500. Analysts expect a Q4 EPS of -$0.66 and revenue of $78.41 million, with full-year forecasts showing significant growth in both earnings and revenue, while the stock currently holds a Zacks Rank of #3 (Hold).

https://www.nasdaq.com/articles/novavax-nvax-rises-market-takes-dip-key-facts

The Truth About Novavax Inc (NVAX): Comeback Story or Total Bag Fumble?

This article examines Novavax Inc (NVAX) to determine if it's a potential comeback story or a high-risk investment. It discusses the mixed sentiment around the stock, its protein-based vaccine technology, and its volatility. The piece concludes that NVAX is a speculative play for risk-tolerant investors rather than a core portfolio holding.

https://www.ad-hoc-news.de/boerse/news/ueberblick/the-truth-about-novavax-inc-nvax-comeback-story-or-total-bag-fumble/68573971

The Truth About Novavax Inc (NVAX): Comeback Story or Total Bag Fumble?

Novavax stock (NVAX) is experiencing renewed interest, appearing on watchlists and social media discussions as a potential biotech comeback. The article explores whether NVAX is a viable investment, highlighting its protein-based vaccine technology as an alternative to mRNA, while also cautioning about its high volatility, significant competition, and the inherent risks for investors seeking high-reward opportunities.

https://www.ad-hoc-news.de/boerse/ueberblick/the-truth-about-novavax-inc-nvax-comeback-story-or-total-bag-fumble/68573971

Novavax (NVAX) Rises As Market Takes a Dip: Key Facts

Novavax (NVAX) saw a 2.51% increase in its stock price, closing at $8.97, while the broader market indices like the S&P 500, Dow, and Nasdaq experienced slight declines. The vaccine maker is anticipated to report an EPS of -$0.66 and revenue of $78.41 million in its upcoming earnings release. Novavax currently holds a Zacks Rank of #3 (Hold) within the Medical - Biomedical and Genetics industry.

https://sg.finance.yahoo.com/news/novavax-nvax-rises-market-takes-224502448.html

Human Vaccine Adjuvants Market Forecast with Size and Share Analysis 2026 to 2035

The Human Vaccine Adjuvants Market is projected to grow from USD 4.16 billion in 2025 to USD 5.62 billion by 2035, exhibiting a CAGR of 3.2%. This growth is driven by the rising incidence of infectious diseases, advancements in vaccine technology, and increasing global focus on personalized medicine. North America currently leads the market, while high development costs pose a significant challenge.

https://www.insightaceanalytic.com/report/human-vaccine-adjuvants-market/3441

Trending Today

Ethereum ($ETH) Crypto Forecast: Up 5.6% Today

Solana ($SOL) Crypto Forecast: Up 7.9% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.1% Today

Albemarle Corporation ($ALB) Stock Forecast: Up 5.8% Today

Sonos Inc. ($SONO) Stock Forecast: Down 5.2% Today

Franco-Nevada Corp. ($FNV) Stock Forecast: Up 5.1% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Up 7.6% Today

Rocket Companies Inc ($RKT) Stock Forecast: Up 5.1% Today

Jetblue Airways Corporation ($JBLU) Stock Forecast: Up 5.4% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Up 6.5% Today

Novavax Inc. Price History

05.01.2026 - NVAX Stock was down 5.1%

• Novavax's stock showed a decline compared to the general market performance today.
• The drop in NVAX's stock value may be linked to the upcoming earnings report, which is anticipated to reveal negative earnings per share (EPS) and revenue numbers for the quarter.
• Despite the approval from the FDA for Novavax's COVID-19 vaccine, the stock encountered selling pressure, possibly due to profit-taking or market sentiment.
• The recent reevaluation of NVAX to a "sell" rating by Wall Street Zen could have also contributed to the downward trend, highlighting worries about the company's financial position and worth.

30.00.2026 - NVAX Stock was down 5.3%

• Novavax's stock faced a downward trend despite the announcement of a licensing agreement with Pfizer for its Matrix-M adjuvant technology, which is viewed as a potential source of significant revenue.
• The decline in stock price may be linked to concerns regarding the company's core business in coronavirus vaccines, revenue inconsistencies, and challenges in internal vaccine development, as highlighted in recent discussions.
• There has been a notable increase in short interest and negative market sentiment towards Novavax, with a notably higher short interest compared to similar companies, potentially influencing the stock's downturn.
• Investors are awaiting Novavax's upcoming earnings report, anticipating a year-over-year decline in EPS and revenue, contributing to a cautious sentiment regarding the stock's future despite recent positive developments.

13.01.2026 - NVAX Stock was up 5.1%

• Novavax (NVAX) stock showed resilience today, increasing by 2.51% while major indices such as the S&P 500, Dow, and Nasdaq faced minor declines.
• Analysts hold a positive outlook on Novavax's upcoming financial performance, anticipating substantial growth in earnings and revenue, which is likely fueling the favorable market sentiment towards the stock.
• Investor interest in Novavax as a potential biotech success story, alongside its protein-based vaccine technology as an alternative to mRNA, has attracted capital despite the stock's inherent volatility and competition in the sector.
• Anticipated expansion in the Human Vaccine Adjuvants Market is also instilling confidence in Novavax's future potential, supported by ongoing advancements in vaccine technology and the global emphasis on personalized medicine driving industry growth.

12.01.2026 - NVAX Stock was down 5.9%

• Speculation regarding NVAX's potential resurgence in the biotech sector could have heightened stock volatility.
• Allianz Asset Management GmbH's notable increase in NVAX stake likely boosted investor confidence initially, though subsequent profit-taking actions may have contributed to the bearish trend.
• Despite exceeding revenue expectations, investors may have been deterred by mixed sentiment and concerns regarding the stock's high volatility and risks.
• Market-wide declines in key indices like the S&P 500, Dow, and Nasdaq may have exerted additional selling pressure on NVAX, impacting its performance despite positive company updates.

28.00.2026 - NVAX Stock was down 5.1%

• The bearish movement in NVAX stock today may be attributed to concerns about the company's lack of growth prospects despite the recent surge in share price.
• The licensing agreement with Pfizer, though positive for industry validation and potential revenue streams, may not have been enough to offset investor worries about the company's future growth.
• The underperformance of NVAX compared to the broader market gains could have also contributed to the downward pressure on the stock today.
• Overall, the market sentiment towards NVAX seems to be cautious due to uncertainties surrounding its growth trajectory and revenue forecasts, leading to the bearish movement observed today.

28.00.2026 - NVAX Stock was down 5.1%

• The decline in NVAX stock today might be due to profit-taking following a recent rise in share price, along with concerns about the company's revenue forecast and growth outlook.
• While the collaboration with Pfizer is a positive step, it may not have been sufficient to maintain positive momentum, especially as some analysts have raised alerts about execution risks and potential revenue declines.
• The significant increase in the purchasing of call options suggests short-term optimism, but overall sentiment appears cautious due to the company's modest growth prospects.
• Investors are eagerly anticipating Novavax's forthcoming financial results, which are expected to reveal a decrease in EPS and revenue for the quarter, potentially exerting further downward pressure on the stock.

22.00.2026 - NVAX Stock was up 9.1%

• The bullish movement in NVAX today can be attributed to the significant licensing agreement with Pfizer, which includes upfront payment, potential milestones, and royalties, boosting investor confidence and leading to a surge in the stock price.
• The high volume of call options being bought indicates short-term bullish sentiment among traders, further driving up the stock price.
• Despite the positive news and reiterated "Buy" ratings from analysts, there are concerns about execution risks and revenue declines, leading to a divided opinion among analysts and hedge funds.
• While NVAX presents a unique opportunity in the vaccine market, the stock's volatility and speculative nature suggest that it may be more suitable for traders seeking short-term gains rather than long-term stability.

23.00.2026 - NVAX Stock was down 5.1%

• The recent 46% surge in Novavax's stock price sparked concerns over the company's growth potential, with analysts foreseeing a substantial revenue decline in contrast to industry trends. This disparity is likely driving the prevailing bearish sentiment surrounding NVAX.
• Despite a favorable non-exclusive licensing agreement with Pfizer and a rise in call options indicating short-term bullish sentiment, fears related to execution risks and revenue decreases are tempering overall investor confidence in Novavax.
• The significant deal with Pfizer, which involved a sizeable upfront payment and potential milestones, was initially well-received, leading to a stock price increase. However, uncertainties surrounding Novavax's growth path and financial prospects may be overshadowing the immediate advantages of the collaboration.
• Analyst perspectives on NVAX are divided, with some firms maintaining a "Buy" rating while others adjusting price targets downwards. This diverse outlook, combined with worries about the company's valuation and revenue projections, could be contributing to today's bearish market activity.

03.01.2026 - NVAX Stock was down 5.0%

• The FDA approval of Novavax's COVID-19 vaccine raised expectations, but the stock saw a downward trend, possibly due to profit-taking.
• Despite securing a licensing agreement with Pfizer for its Matrix M adjuvant, Wall Street Zen's downgrade to a "sell" rating caused stock pressure amid concerns about financial performance.
• BofA's increased price target and positive options activity generated some optimism. However, uncertainties over asset development timing under the license tempered investor enthusiasm.
• Pfizer's strategic collaborations with Novavax and other developments may have indirectly influenced Novavax's stock movement as investors reevaluated the pharmaceutical industry landscape.

21.00.2026 - NVAX Stock was up 20.0%

• The rise in NVAX today is possibly linked to a new license agreement with Pfizer, indicating a temporary positive outlook among investors.
• Renewed support from BTIG, maintaining a "Buy" rating with a $19 price target, has bolstered confidence in NVAX's potential, despite differing analyst perspectives and adjustments from other companies.
• The CEO's focus on the success of the company's Matrix-M technology and growth strategy during the J.P. Morgan Healthcare Conference likely played a part in the favorable market movement, underscoring Novavax's standing in the global vaccine industry.
• Despite uncertainties regarding execution risks and revenue drops, the generally upbeat news related to NVAX's partnerships and vaccine technology appears to have eclipsed the cautious views, propelling the stock upwards.

21.00.2026 - NVAX Stock was up 9.5%

• BTIG's reaffirmation of a "Buy" rating and $19 price target for NVAX demonstrates that investors have confidence in the stock's potential, contributing to its strong uptrend.
• NVAX's emphasis on its Matrix-M technology, alliances with key partners, and efficient operational approach, as discussed in a recent healthcare conference, likely bolstered investor confidence.
• The company's transition to a partnership-centered strategy with profitability goals for 2028 through collaborations and expense management appears to have resonated positively with traders eyeing long-term growth prospects.
• Despite potential risks associated with NVAX, the market is evidently reacting favorably to the company's strategic moves and opportunities for market expansion through its vaccine portfolio and partnerships.

10.01.2026 - NVAX Stock was up 6.6%

• Novavax stock showed bullish movement today, outperforming major market indices like the S&P 500, Dow, and Nasdaq.
• This positive trend is linked to Allianz Asset Management GmbH significantly increasing its stake in Novavax, Inc. by 162.6% in the third quarter, showcasing confidence in the company's future.
• The growth forecast for the Human Vaccine Adjuvants Market, where Novavax is a key player, likely boosted optimism around the stock.
• Despite facing challenges like negative free cash flow and revenue decline, analysts foresee a potential 48% upside for Novavax. It's vital to closely monitor strategic developments and regulatory milestones due to the speculative nature of this opportunity.